KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Retained Earnings (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Retained Earnings data on record, last reported at $77.5 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 99.76% year-over-year to $77.5 million; the TTM value through Dec 2025 reached $77.5 million, down 99.76%, while the annual FY2025 figure was $77.5 million, 99.76% down from the prior year.
  • Retained Earnings reached $77.5 million in Q4 2025 per REGN's latest filing, down from $35.0 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $35.0 billion in Q3 2025 and bottomed at -$181.6 million in Q1 2023.
  • Average Retained Earnings over 5 years is $17.4 billion, with a median of $20.8 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 122997.53% in 2022, then plummeted 100.91% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $16.7 billion in 2021, then skyrocketed by 39.23% to $23.3 billion in 2022, then plummeted by 100.35% to -$80.9 million in 2023, then skyrocketed by 39250.68% to $31.7 billion in 2024, then plummeted by 99.76% to $77.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $77.5 million in Q4 2025, $35.0 billion in Q3 2025, and $33.7 billion in Q2 2025.